Nicox SA Stock BOERSE MUENCHEN

NXOA

FR0013018124

Pharmaceuticals

Market Closed - BOERSE MUENCHEN Other stock markets 06:43:55 01/08/26 am AEST			5-day change	1st Jan Change
0.3620 ^EUR	-.--%		-.--%	+21.68%

01/07	Nicox Submits NCX 470 New Drug Application In The United States	CI
01/07	Nicox files U.S. marketing approval application

News in other languages: Nicox SA

01/07	Bourse : Schneider se renforce dans l'IA, Air Liquide investit pour SK Hynix, Nike déçoit
01/07	Nicox dépose une demande d'autorisation de mise sur le marché aux Etats-Unis
01/07	La Bourse s'habitue à tout
01/07	Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
23/06	Bourse : Sanofi enchaîne les AMM, Prysmian enchaîne les contrats, l'IA enchaîne les dépenses

More news

Managers and Directors: Nicox SA

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	28/02/2024
Sandrine Gestin DFI	Director of Finance/CFO	58	01/01/2015
Doug Hubatsch CTO	Chief Tech/Sci/R&D Officer	-	13/12/2021

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	08/04/2024
Damian Marron CHM	Chairman	64	16/07/2024
Marc Bozec BRD	Director/Board Member	-	16/07/2024

More insiders

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX SA	-.--%	-.--%	+1.83%	-16.49%	39.18M
MERCK & CO., INC.	+0.32%	-0.66%	+64.21%	+23.18%	322B
MERCK KGAA	+0.21%	+2.87%	+33.60%	-10.00%	71.6B
HALOZYME THERAPEUTICS, INC.	-0.91%	+0.74%	+39.85%	+92.63%	9.79B
KYOWA KIRIN CO., LTD.	-2.99%	-6.76%	-3.26%	-8.79%	8.39B
SK BIOPHARMACEUTICALS CO., LTD.	+1.80%	-1.99%	-15.78%	-13.19%	4.3B
YUHAN CORPORATION	-0.68%	-1.87%	-34.78%	+6.01%	3.81B
BETTA PHARMACEUTICALS CO., LTD.	+3.08%	-1.41%	-12.94%	+15.81%	3.58B
SUPERNUS PHARMACEUTICALS, INC.	-2.15%	-3.40%	+25.70%	+41.55%	2.59B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+0.85%	+9.88%	-0.25%	-3.21%	2.25B
Average	-0.04%	-0.34%	+9.82%	+12.75%	47.54B
Weighted average by Cap.	+0.23%	-0.09%	+54.30%	+17.98%

See all sector performances

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
31/07/26	EUR 0.3620	-.--%
30/07/26	EUR 0.3620	-.--%
29/07/26	EUR 0.3620	-.--%
28/07/26	EUR 0.3620	-.--%
27/07/26	EUR 0.3620	-.--%

Real-time BOERSE MUENCHEN

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3865EUR

Average target price

1.000EUR

Spread / Average Target

+158.73%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

As early as today, start finding the best investment opportunities!

Market Cap	34.06M 39.18M 31.7M 29.11M 54.97M 3.74B 55.82M 374M 147M 1.86B 147M 144M 6.24B	P/E 2026 *	-5.52x	P/E 2027 *	38.7x
Enterprise Value	34.06M 39.18M 31.7M 29.11M 54.97M 3.74B 55.82M 374M 147M 1.86B 147M 144M 6.24B	EV / Sales 2026 *	11.4x	EV / Sales 2027 *	3.41x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

01/07	Nicox Submits NCX 470 New Drug Application In The United States	CI
01/07	Nicox files U.S. marketing approval application
23/06	Nicox Bags EUR6 Million Shareholder Loan	MT
23/06	Nicox Secures Backing From a Shareholder and Financial Partner
18/06	Nicox Receives Positive Feedback from China
18/06	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470	CI
30/04	Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
24/02	Nicox SA Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting	CI
24/02	Edenred, Forvia, Freelance.com... Key Stocks to Watch Today in Paris -
24/02	Nicox Reports Positive Phase 3 Results for NCX 470
16/02	Nicox, Sanofi, Valneva... Stocks to Watch Today in Paris
16/02	Nicox Moves Forward with U.S. Health Authorities for Its NCX 470
05/01	Nicox Strengthens Its Financial Position

01/07	Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment	GL
23/06	Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company	GL
18/06	Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470	GL
08/06	Reminder: Nicox June 2024 Warrants will expire June 19, 2026	GL
03/06	Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative	GL

1 month	-2.69%
3 months	-8.24%
6 months	-4.74%
Current year	+21.68%

1 week	0.36	0.39
1 month	0.36	0.39
3 years	0.15	0.65
5 years	0.15	3.82

Nicox SA Stock BOERSE MUENCHEN

Stocks

NXOA

FR0013018124

Pharmaceuticals

Valuation: Nicox SA

Chart: Nicox SA

Latest news : Nicox SA

Press Releases: Nicox SA

News in other languages: Nicox SA

Quotes and Performance

Course Extremes

Managers and Directors: Nicox SA

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

	2026 *	2027 *
Net sales	3M 3.45M 2.79M 2.56M 4.84M 329M 4.92M 32.91M 12.92M 164M 12.96M 12.68M 550M	10M 11.5M 9.31M 8.55M 16.14M 1.1B 16.39M 110M 43.06M 547M 43.2M 42.25M 1.83B
Net income	-6M -6.9M -5.58M -5.13M -9.68M -659M -9.83M -65.83M -25.84M -328M -25.92M -25.35M -1.1B	1M 1.15M 931K 855K 1.61M 110M 1.64M 10.97M 4.31M 54.67M 4.32M 4.23M 183M
Net Debt	-	-